08.07.13
James Corrigan has been appointed executive vice president and chief operating officer at ERT. Mr. Corrigan will be responsible for overseeing and developing the strategic direction for operations, including services, product management, IT, account management, marketing, quality, and R&D, to support systems for the collection of patient endpoint data.
He joins the company from General Electric, where he spent more than 25 years in senior management positions, including most recently as chief executive officer of the Surgery business. While at GE, he successfully advanced sales growth, marketing, strategic partnerships, business development, integrations, product development, operations and customer service excellence.
“The growth of ERT has given us the opportunity to expand our team with talented individuals from the healthcare industry,” said Jeffrey Litwin, M.D., chief executive officer of ERT. “We are delighted to have Jim on board in this leadership role, and we look forward to leveraging his extensive healthcare experience and proven success to help us expand our foundation for future growth, strengthen the breadth of services and solutions that ERT provides to the biopharmaceutical market, and create further value enhancement for our customers.”
He joins the company from General Electric, where he spent more than 25 years in senior management positions, including most recently as chief executive officer of the Surgery business. While at GE, he successfully advanced sales growth, marketing, strategic partnerships, business development, integrations, product development, operations and customer service excellence.
“The growth of ERT has given us the opportunity to expand our team with talented individuals from the healthcare industry,” said Jeffrey Litwin, M.D., chief executive officer of ERT. “We are delighted to have Jim on board in this leadership role, and we look forward to leveraging his extensive healthcare experience and proven success to help us expand our foundation for future growth, strengthen the breadth of services and solutions that ERT provides to the biopharmaceutical market, and create further value enhancement for our customers.”